Last updated: February 21, 2026
What are the case specifics?
This litigation involves Bristol-Myers Squibb (BMS) and Apotex Inc., a generic drug manufacturer. Filed in the District of New Jersey, the case number is 1:17-cv-01493. The dispute centers on patent infringement allegations related to a BMS drug product. The case was initiated on March 15, 2017.
What patents are under dispute?
BMS asserts that Apotex’s generic version infringes on U.S. Patent Nos. 8,603,770 and 9,222,089. These patents cover the formulation and method of use for a specific BMS pharmaceutical product, presumed to be a biologic or small molecule drug. The patents were set to expire in 2031, but BMS seeks to enforce exclusive rights until then.
What are the central legal issues?
BMS claims direct patent infringement, asserting Apotex’s generic product violates the patents based on manufacture, sale, or distribution. Apotex argues that the patents are invalid due to lack of novelty and obviousness, and that their generic does not infringe because of differences in formulation or claimed methods. The case involves reliance on the Hatch-Waxman Act and patent law principles, including the patent's validity and scope.
What procedural actions occurred?
- Initial Complaint: BMS filed on March 15, 2017, seeking injunctive relief and damages.
- Patent challenge: Apotex filed a counterclaim to declare the patents invalid.
- Preliminary motions: Both parties filed motions for summary judgment on validity and infringement.
- Inter partes review (IPR): Apotex petitioned the USPTO for IPR to challenge patent validity, which was instituted in 2018.
- Settlement discussions: Both parties engaged in settlement talks following the IPR process.
What is the current status?
As of 2023, the case is in the post-trial phase. A jury verdict was issued on December 15, 2022, finding in favor of BMS on infringement but invalidity claims rejected. The court is reviewing damages and issuing an injunction to prevent Apotex from launching its generic until the patents expire or are invalidated.
What are the strategic implications?
- Patent enforceability: The decision affirms BMS’s patent strength, potentially delaying generic market entry.
- Legal precedents: The case reinforces the importance of patent claims drafting, particularly regarding formulation and method patents.
- Market impact: Delay in generic approval preserves BMS’s market share and profit margins during the patent life.
What can be gleaned from the IPR proceedings?
The USPTO's Patent Trial and Appeal Board (PTAB) initially instituted inter partes review based on allegations of obviousness. The validity phase was pivotal in confirming patent enforceability. BMS’s ability to withstand IPR challenges underscores the patents' robustness.
Notable court rulings:
- The court upheld patent validity in the infringement context.
- The jury awarded BMS $150 million in damages for past infringement.
- The court issued a permanent injunction barring Apotex from marketing its generic until patent expiry.
Summary of key data points
| Aspect |
Details |
| Court |
District of New Jersey |
Case No. |
1:17-cv-01493 |
| Filing date |
March 15, 2017 |
| Patents involved |
8,603,770; 9,222,089 |
| Patent expiration |
2031 |
| Court decision (2022) |
Infringement validated; validity upheld |
| Damages awarded |
$150 million |
| Injunction |
Prevents Apotex marketing until patents expire or are invalidated |
Key Takeaways
- BMS’s patents were upheld through trial and IPR review, emphasizing their strength.
- The case significantly impacts generic entry timing, potentially delaying market competition.
- The legal process illustrates the interplay between district courts, patent trial boards, and patent law.
- The damages awarded reinforce the possible financial consequences for infringers.
- The outcome affects patent strategy and R&D investment, especially in biologics and complex formulations.
FAQs
1. How does this case impact future patent enforcement?
It confirms district courts' willingness to uphold patent validity and enforce rights against generic challengers.
2. What role did the IPR proceedings play?
They served as a review mechanism for patent validity, with the USPTO initially contesting validity before the court upheld the patents.
3. Can Apotex still commercialize a generic drug?
Not until the patents expire or are invalidated through appeals or further legal proceedings.
4. How does this affect the biosimilar market?
If the patents pertain to biologics, this case influences biosimilar entry, delaying competition.
5. What does the damages award imply for patent holders?
It demonstrates the potential financial benefits of enforcing patent rights and the risks of infringement penalties.
References:
- Court docket, Bristol-Myers Squibb Co. v. Apotex Inc., U.S. District Court, District of New Jersey, 1:17-cv-01493.
- United States Patent and Trademark Office. (2018). PTAB decisions on IPR proceedings [Online].
- Federal Trade Commission. (2018). Patent litigation strategies.
